Literature DB >> 8792779

Estimating the dollar value of health outcomes from drug-abuse interventions.

M T French1, J A Mauskopf, J L Teague, E J Roland.   

Abstract

OBJECTIVES: People who abuse drugs suffer from a host of medical problems that impose costs on both the abusers and society as a whole. Drug-abuse treatment and other interventions can help alleviate these medical problems, leading to health status improvements for chronic drug users and reduced social costs. The authors' dual purpose here is to (1) propose a theoretically rigorous yet easy-to-apply methodology for estimating the health-related costs of drug abuse and (2) demonstrate the methodology by estimating the potential dollar value of avoiding adverse health consequences as a result of successful drug-abuse interventions.
METHODS: The authors' proposed multiattribute quality-adjusted life year methodology for estimating the value of avoiding morbidity and mortality involves eight steps to be followed sequentially. The framework is based on developing a common unit of well-being (i.e., quality-adjusted life year) that can be applied to all types of health conditions. If all health states can be denominated in this common unit, then the process of valuation is straightforward and consistent across all types of illnesses and diseases. The methodology is relatively inexpensive to execute because the estimation procedures are not complicated technically and the data demands are modest. Also, this approach incorporates elements from several disciplines, including psychology, epidemiology, medicine, and economics. Finally, the proposed methodology is flexible enough to cover a wide range of illnesses and diseases so that consistent and comparable estimates can be generated.
RESULTS: The authors estimate the dollar value of avoiding acute hepatitis B, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hypertension, bacterial pneumonia, sexually transmitted diseases, and tuberculosis for a white male aged 32 years. The authors' results illustrate that estimated avoided morbidity values can vary significantly across the range of health consequences associated with drug abuse. At the upper end of the range, the value of avoiding only the morbidity associated with a single case of HIV/AIDS is approximately $157,811 for the period beginning with transmission of HIV, through late-stage HIV and AIDS, and ending just before death.
CONCLUSIONS: People who abuse drugs suffer from many medical problems in addition to their addiction. The proposed approach for estimating the dollar value of avoiding adverse health consequences provides policy analysts, evaluators, and researchers a method to calculate theoretically based benefit estimates for use in a benefit-cost analysis of drug-abuse interventions.

Entities:  

Mesh:

Year:  1996        PMID: 8792779     DOI: 10.1097/00005650-199609000-00003

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  19 in total

Review 1.  The cost-effectiveness of substance abuse treatment.

Authors:  P G Barnett
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

2.  Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.

Authors:  Michael T French; Helena J Salomé; Jody L Sindelar; A Thomas McLellan
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

3.  Methadone dosing, heroin affordability, and the severity of addiction.

Authors:  P B Bach; J Lantos
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

4.  Contextual determinants of drug use risk behavior: a theoretic framework.

Authors:  Sandro Galea; Jennifer Ahern; David Vlahov
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

5.  Creating an aggregate outcome index: cost-effectiveness analysis of substance abuse treatment.

Authors:  Mireia Jofre-Bonet; Jody L Sindelar
Journal:  J Behav Health Serv Res       Date:  2004 Jul-Sep       Impact factor: 1.505

6.  Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs.

Authors:  Todd A Olmstead; Jody L Sindelar; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2006-09-12       Impact factor: 4.492

7.  Evaluating Alternative Aftercare Models for Ex-Offenders.

Authors:  Leonard A Jason; Bradley D Olson; Ron Harvey
Journal:  J Drug Issues       Date:  2015-01

8.  Cost outcome analysis in injury prevention and control: a primer on methods.

Authors:  T R Miller; D T Levy
Journal:  Inj Prev       Date:  1997-12       Impact factor: 2.399

9.  Economic valuation of the potential health benefits from foods enriched with plant sterols in Canada.

Authors:  Collin L Gyles; Jared G Carlberg; Jennifer Gustafson; David A Davlut; Peter J H Jones
Journal:  Food Nutr Res       Date:  2010-10-07       Impact factor: 3.894

10.  The sensitivity of substance abuse treatment intensity to co-payment levels.

Authors:  Anthony T Lo Sasso; John S Lyons
Journal:  J Behav Health Serv Res       Date:  2004 Jan-Mar       Impact factor: 1.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.